Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | LTA4H | P09960 | 2/20 | 0.57 |
| ▸ | ESR1 | P03372 | 1/20 | 0.55 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.55 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.55 |
| ▸ | RXRA | P19793 | 1/20 | 0.55 |
| ▸ | RXRB | P28702 | 1/20 | 0.55 |
| ▸ | PPARG | P37231 | 3/20 | 0.49 |
| ▸ | PRKCA | P17252 | 1/20 | 0.49 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.49 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.49 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.48 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2659405 | 0.91 | KMT2A (0.53) | KMT2AMEN1ALDH1A1LMNALTA4H | |
| SCHEMBL2656926 | 0.90 | KMT2A (0.53) | KMT2AMEN1ALDH1A1LMNALTA4H | |
| SCHEMBL14021656 | 0.88 | ESR1 (0.72) | KMT2AMEN1LMNALTA4HESR1 | |
| SCHEMBL11999235 | 0.84 | ESR1 (0.54) | KMT2AMEN1ALDH1A1LMNAESR1 | |
| SCHEMBL2669617 | 0.84 | ESR1 (0.54) | KMT2AMEN1ALDH1A1LMNAESR1 | |
| SCHEMBL2656320 | 0.83 | ESR1 (0.81) | KMT2AMEN1ALDH1A1LMNAESR1 | |
| SCHEMBL2657472 | 0.81 | GCGR (0.49) | KMT2AMEN1ALDH1A1LMNAESR1 | |
| SCHEMBL11999234 | 0.80 | ESR1 (0.62) | KMT2AMEN1ALDH1A1LMNAESR1 | |
| SCHEMBL2662588 | 0.80 | PPARG (0.48) | KMT2AMEN1ALDH1A1LMNANR4A2 | |
| SCHEMBL2669746 | 0.80 | ESR1 (0.50) | KMT2AMEN1ALDH1A1LMNAESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10807946-B2 | Antagonists of the glucagon receptor | METABASIS THERAPEUTICS, INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-10807946-B2 | Antagonists of the glucagon receptor | METABASIS THERAPEUTICS, INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-20190218176-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2019-07-18 | — | — | US | disclosed |
| US-20190218176-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2019-07-18 | — | — | US | disclosed |
| US-10239829-B2 | Antagonists of the glucagon receptor | METABASIS THERAPEUTICS, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| US-10239829-B2 | Antagonists of the glucagon receptor | METABASIS THERAPEUTICS, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| EP-2786985-B1 | Antagonists of the glucagon receptor | METABASIS THERAPEUTICS INC (US) | 2018-11-28 | — | — | EP | disclosed |
| US-20170275246-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | METABASIS THERAPEUTICS, INC. | 2017-09-28 | — | — | US | disclosed |
| US-20170275246-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | METABASIS THERAPEUTICS, INC. | 2017-09-28 | — | — | US | disclosed |
| US-9701626-B2 | Antagonists of the glucagon receptor | METABASIS THERAPEUTICS, INC. (US) | 2017-07-11 | — | — | US | disclosed |
| US-9701626-B2 | Antagonists of the glucagon receptor | METABASIS THERAPEUTICS, INC. (US) | 2017-07-11 | — | — | US | disclosed |
| US-20160009639-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | METABASIS THERAPEUTICS INC (US) | 2016-01-14 | — | — | US | disclosed |
| US-9169201-B2 | Antagonists of the glucagon receptor | METABASIS THERAPEUTICS, INC. (US) | 2015-10-27 | — | — | US | disclosed |
| EP-2786985-A2 | Antagonists of the glucagon receptor | Metabasis Therapeutics, Inc. (US) | 2014-10-08 | — | — | EP | disclosed |
| EP-2129654-B1 | ANTAGONISTS OF THE GLUCAGON RECEPTOR | METABASIS THERAPEUTICS INC (US) | 2014-05-28 | — | — | EP | disclosed |
| US-20140135400-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | METABASIS THERAPEUTICS, INC. (US) | 2014-05-15 | — | — | US | disclosed |
| US-8710236-B2 | Antagonists of the glucagon receptor | METABASIS THERAPEUTICS, INC. (US) | 2014-04-29 | — | — | US | disclosed |
| US-20120214769-A1 | Novel Antagonists of the Glucagon Receptor | METABASIS THERAPEUTICS, INC. (US) | 2012-08-23 | — | — | US | disclosed |
| EP-2129654-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | Metabasis Therapeutics, Inc. (US) | 2009-12-09 | — | — | EP | disclosed |
| WO-2008098244-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | METABASIS THERAPEUTICS, INC. (US) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160009639-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | GLP1R, GCGR, GPR119 | KMT2A 4280/4885MEN1 2416/4885ALDH1A1 4642/4885 |
| US-20190218176-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | GLP1R, GCGR, GPR119 | KMT2A 4300/4885MEN1 2437/4885ALDH1A1 4644/4885 |
| US-10239829-B2 | Antagonists of the glucagon receptor | GLP1R, GCGR, GPR119 | KMT2A 4130/4885MEN1 2359/4885ALDH1A1 4662/4885 |
| US-20140135400-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | GLP1R, GCGR, GPR119 | KMT2A 4280/4885MEN1 2416/4885ALDH1A1 4642/4885 |
| US-20120214769-A1 | Novel Antagonists of the Glucagon Receptor | GLP1R, GCGR, GPR119 | KMT2A 4280/4885MEN1 2416/4885ALDH1A1 4642/4885 |
| US-20170275246-A1 | NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR | GLP1R, GCGR, GPR119 | KMT2A 4280/4885MEN1 2416/4885ALDH1A1 4642/4885 |
| US-10807946-B2 | Antagonists of the glucagon receptor | GLP1R, GCGR, GPR119 | KMT2A 4122/4885MEN1 2282/4885ALDH1A1 4657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.